Background:Collagen type Ⅳ(COL4)-related nephropathy includes a variety of kidney diseases that occur with or without extra-renal manifestations caused by COL4A3-5 mutations.Previous studies revealed several novel mu...Background:Collagen type Ⅳ(COL4)-related nephropathy includes a variety of kidney diseases that occur with or without extra-renal manifestations caused by COL4A3-5 mutations.Previous studies revealed several novel mutations,including three COL4A3 missense mutations (G619R,G801R,and C1616Y) and the COL4A3 chr:228172489delA c.4317delA p.Thr1440ProfsX87 frameshift mutation that resulted in a truncated NC1 domain (hereafter named COL4A3 c.4317delA);however,the mutation mechanisms that lead to podocyte injury remain unclear.This study aimed to further explore the mutation mechanisms that lead to podocyte injury.Methods:Wild-type (WT) and four mutant COL4A3 segments were constructed into a lentiviral plasmid,then stably transfected into human podocytes.Real-time polymerase chain reaction and Western blotting were applied to detect endoplasmic reticulum stress (ERS)-and apoptosis-related mRNA and protein levels.Then,human podocytes were treated with MG132 (a proteasome inhibitor) and brefeldin A (a transport protein inhibitor).The human podocyte findings were verified by the establishment of a mus-Col4a3 knockout mouse monoclonal podocyte using clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Casg) technology.Results:Our data showed that COL4A3 mRNA was significantly overexpressed in the lentivirus stably transfected podocytes.Moreover,the COL4A3 protein level was significantly increased in all groups except the COL4A3 c.4317delA group.Compared to the other test groups,the COL4A3 c.4317delA group showed excessive ERS and apoptosis.Podocytes treated with MG 132 showed remarkably increased intra-cellular expression of the COL4A3 c.4317delA mutation.MG132 intervention improved higher ERS and apoptosis levels in the COL4A3 c.4317delA group.Mouse monoclonal podocytes with COL4A3 chr:82717932insA c.4852insA p.Arg1618ThrfsX4 were successfully acquired;this NC1-truncated mutation suggested a higher level of ERS and relatively remarkable level of apoptosis compared to that of the WT group.Conclusions:We demonstrated that excessive ERS and ERS-induced apoptosis were involved in the podocyte injury caused by the NC1-truncated COL4A3 mutation.Furthermore,proteasome pathway intervention might become a potential treatment for collagen type Ⅳ-related nephropathy caused by a severely truncated COL4A3 mutation.展开更多
基金grants from the National Key Research and Development Program of China (No. 2016YFC0904100)National Natural Science Foundation of China (Nos. 81870460, 81570598, and 81370015)+3 种基金Science and Technology Innovation Action Plan of Shanghai Science and Technology Committee (No. 17441902200)Shanghai Municipal Education Commission, Gaofeng Clinical Medicine Grant (No. 20152207)Shanghai Jiao Tong University School of Medicine, MultiCenter Clinical Research Project (No. DLY201510)the Shanghai Health and Family Planning Committee Hundred Talents Program (No. 2018BR37).
文摘Background:Collagen type Ⅳ(COL4)-related nephropathy includes a variety of kidney diseases that occur with or without extra-renal manifestations caused by COL4A3-5 mutations.Previous studies revealed several novel mutations,including three COL4A3 missense mutations (G619R,G801R,and C1616Y) and the COL4A3 chr:228172489delA c.4317delA p.Thr1440ProfsX87 frameshift mutation that resulted in a truncated NC1 domain (hereafter named COL4A3 c.4317delA);however,the mutation mechanisms that lead to podocyte injury remain unclear.This study aimed to further explore the mutation mechanisms that lead to podocyte injury.Methods:Wild-type (WT) and four mutant COL4A3 segments were constructed into a lentiviral plasmid,then stably transfected into human podocytes.Real-time polymerase chain reaction and Western blotting were applied to detect endoplasmic reticulum stress (ERS)-and apoptosis-related mRNA and protein levels.Then,human podocytes were treated with MG132 (a proteasome inhibitor) and brefeldin A (a transport protein inhibitor).The human podocyte findings were verified by the establishment of a mus-Col4a3 knockout mouse monoclonal podocyte using clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Casg) technology.Results:Our data showed that COL4A3 mRNA was significantly overexpressed in the lentivirus stably transfected podocytes.Moreover,the COL4A3 protein level was significantly increased in all groups except the COL4A3 c.4317delA group.Compared to the other test groups,the COL4A3 c.4317delA group showed excessive ERS and apoptosis.Podocytes treated with MG 132 showed remarkably increased intra-cellular expression of the COL4A3 c.4317delA mutation.MG132 intervention improved higher ERS and apoptosis levels in the COL4A3 c.4317delA group.Mouse monoclonal podocytes with COL4A3 chr:82717932insA c.4852insA p.Arg1618ThrfsX4 were successfully acquired;this NC1-truncated mutation suggested a higher level of ERS and relatively remarkable level of apoptosis compared to that of the WT group.Conclusions:We demonstrated that excessive ERS and ERS-induced apoptosis were involved in the podocyte injury caused by the NC1-truncated COL4A3 mutation.Furthermore,proteasome pathway intervention might become a potential treatment for collagen type Ⅳ-related nephropathy caused by a severely truncated COL4A3 mutation.